June 1, 2024Journal of Clinical Oncology

Real-world efficacy and adverse events of neoadjuvant immunotherapy in patients with early-stage triple-negative breast cancer: A multi-center experience.

View Full Paper

Ask AI

Bookmark

The pathological complete response rate was 64.8%, indicating effectiveness of the regimen in real-world conditions.
A significant correlation was found between higher absolute eosinophil counts and improved pathological response (OR 4.54).
Analysis employed multivariable logistic regression to evaluate clinical characteristics influencing treatment outcomes and adverse events. 145 patients observed over 12.3 months displayed notable toxicity profile with 48.3% experiencing immune-related adverse events (irAEs).

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Retrospective analysis shows 64.8% pathological complete response in early-stage triple-negative breast cancer, suggesting high immune adverse events.

Cite This Study

Krishnan et al. (2024) studied this question.

synapsesocial.com/papers/68e67050b6db6435875fa629 https://doi.org/10.1200/jco.2024.42.16_suppl.e23293

View Full Paper

Ask AI

Bookmark

Implication

Retrospective analysis shows 64.8% pathological complete response in early-stage triple-negative breast cancer, suggesting high immune adverse events.

Real-world efficacy and adverse events of neoadjuvant immunotherapy in patients with early-stage triple-negative breast cancer: A multi-center experience.

Key Points

Discussion

Implication

Cite This Study

Real-world efficacy and adverse events of neoadjuvant immunotherapy in patients with early-stage triple-negative breast cancer: A multi-center experience.

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider